Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026

What happened

Gilead Sciences and its Kite unit announced 23 presentations, including seven oral presentations, for the American Society of Hematology’s 2026 meeting, scheduled for December 12–15. The topics include investigational anito-cel data in relapsed or refractory multiple myeloma, early results from approaches in lymphoma and autoimmune blood disorders, and longer-term follow-up of existing therapies.

Confirmed

Global impact / market context

The meeting presentations could shape views of Gilead’s blood-cancer and cell-therapy programs by adding clinical evidence for anito-cel and newer approaches. Strong or weak results could influence expectations for future development, spending on trials, and the potential for these programs to contribute to revenue.

Analyst inference

The announcement describes planned research presentations, not a reported approval or a change to current treatment guidance. Anito-cel is identified as investigational, meaning it is still being studied. The article provides no results from the upcoming presentations, so their clinical and commercial implications remain uncertain.

Confirmed

What to watch

1. Review the 18-month minimum follow-up results for the Phase 2 iMMagine-1 study of anito-cel in relapsed or refractory multiple myeloma when they are presented. Confirmed
2. Look for the full findings from the planned presentations, including how many patients benefited, how long responses lasted, and what side effects were reported. Analyst inference
3. Track whether early results in lymphoma and autoimmune blood disorders lead to further studies, which could require additional trial spending before any potential sales. Analyst inference

Evidence

• Original source link unavailable